Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or any ingredient in the formulation.
Hypersensitivity reactions, including anaphylaxis, bronchospasm, and angioedema, may occur. Discontinue immediately if signs of allergic reaction (e.g., pharyngeal edema, urticaria) manifest. Cross-reactivity with inactive components (e.g., sodium thiosulfate) necessitates avoidance.

